Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3 Clinical Trial Required)

0
34

Funding Opportunity ID:310066
Opportunity Number:RFA-CA-19-018
Opportunity Title:Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3 Clinical Trial Required)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Education
Health
Category Explanation:
CFDA Number(s):93.353
93.394
Eligible Applicants:State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Nov 01, 2018
Close Date:Feb 11, 2019
Last Updated Date:Nov 01, 2018
Award Ceiling:$500,000
Award Floor:$0
Estimated Total Program Funding:
Expected Number of Awards:
Description:This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches. The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) program will provide an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of colorectal cancer on the United States (U.S.) population. The UG3/UH3 projects in response to this FOA must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development of one-year, milestone-driven planning phase (UG3), with possible rapid transition to the second phase (UH3) for clinical trials. UH3s will be awarded after administrative review of eligible UG3s that have met the scientific milestones and feasibility requirements necessary for the UH3 phase, depending on availability of funds.
Version:1





Visit the Official Webpage For More Details on Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3 Clinical Trial Required)